Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study

Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study

Abstract Introduction Clinical remission is the main target in the management of patients with rheumatoid arthritis (RA). However, several authors found synovitis in patients with RA in clinical remission at ultrasonography (US). Upadacitinib is a selective Janus kinase 1 inhibitor that achieved sig...

Full description

Bibliographic Details
Main Authors: Andrea Picchianti Diamanti, Maria Sofia Cattaruzza, Simonetta Salemi, Roberta Di Rosa, Giorgio Sesti, Chiara De Lorenzo, Gloria Maria Felice, Bruno Frediani, Caterina Baldi, Maria Sole Chimenti, Arianna D’Antonio, Gloria Crepaldi, Michele Maria Luchetti, Valentino Paci, Alen Zabotti, Ivan Giovannini, Marco Canzoni, Giandomenico Sebastiani, Chiara Scirocco, Carlo Perricone, Bruno Laganà, Annamaria Iagnocco
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-08-01
Series:Rheumatology and Therapy
Subjects:
Clinical remission
Ultrasonographic remission
JAK inhibitors
Upadacitinib
Online Access:https://doi.org/10.1007/s40744-024-00712-y

Internet

https://doi.org/10.1007/s40744-024-00712-y

Similar Items